- Conditions
- Choroidal Neovascularization
- Interventions
- Faricimab, Ranibizumab, Sham Procedure
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 46 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 230
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Age-Related Cognitive Decline, Age-Related Memory Disorders
- Interventions
- DHA (nutritional supplement) or placebo
- Dietary Supplement
- Lead sponsor
- dsm-firmenich Switzerland AG
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 14
- States / cities
- Mesa, Arizona • San Diego, California • Vista, California + 11 more
- Conditions
- Sarcopenia
- Interventions
- Placebo, HMB plus Vitamin D, Non-Exercise, Exercise
- Dietary Supplement · Drug · Behavioral
- Lead sponsor
- Metabolic Technologies Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 238 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Ames, Iowa
- Conditions
- Mild to Heavy Alcohol Consumption
- Interventions
- Oxycodone
- Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Alzheimer Disease, Alzheimer Dementia, Vascular Dementia, Lewy Body Disease, Lewy Body Dementia With Behavioral Disturbance (Disorder), Dementia, Mixed, Parkinson-Dementia Syndrome, Chronic Traumatic Encephalopathy, Huntington's Dementia, Wernicke Korsakoff Syndrome, Traumatic Brain Injury, Dementia, Multi-Infarct, Autism, Autism Spectrum Disorder, Autistic Behavior, Autistic Disorder, Current or Active State, Cadasil, LATE Limbic-predominant Age-related TDP-43 Encephalopathy
- Interventions
- Intravenous Bone Marrow Stem Cell (BMSC) Fraction, Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction, Near Infrared Light
- Procedure
- Lead sponsor
- MD Stem Cells
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 2
- States / cities
- Westport, Connecticut • Coral Springs, Florida
- Conditions
- Choroidal Neovascularization, Age-Related Maculopathy
- Interventions
- dexamethasone, ranibizumab
- Drug · Biological
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Age-Related Macular Degeneration, Choroidal Neovascularization
- Interventions
- IBI-20089/Lucentis
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Choroid Neovascularization, Age-Related Macular Degeneration
- Interventions
- AGN 211745, Ranibizumab 500µg
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neovascularization, Choroidal, Macular Degeneration, Age-Related
- Interventions
- Faricimab, Ranibizumab, Sham Procedure
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 22 more
- Conditions
- Hearing Loss, Depression
- Interventions
- Phonak Audeo B-R 90 hearing aid device (Active), Duloxetine or escitalopram, Audeo B-R 90 hearing aid device (Sham)
- Device · Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 60 Years to 99 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Age-Related Macular Degeneration
- Interventions
- E10030, ranibizumab, E10030 sham intravitreal injection
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 627 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 49
- States / cities
- Tucson, Arizona • Fresno, California • La Jolla, California + 43 more
- Conditions
- Age-related Macular Degeneration, Aging
- Interventions
- Normal Macular Health, Early Macular Degeneration, Young Normals
- Other
- Lead sponsor
- Cynthia Owsley
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 556 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Hearing Loss, Age-Related
- Interventions
- Consult Model, Engage Model
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 684 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Muscle Relaxants
- Interventions
- Not listed
- Lead sponsor
- Shashi Bhatt, MD
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Toledo, Ohio
- Conditions
- Depression, Stress Disorders, Post-traumatic, Bipolar Disorder
- Interventions
- Treatment As Usual, Cornerstone
- Behavioral
- Lead sponsor
- New York University
- Other
- Eligibility
- 17 Years to 18 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Exudative Age-related Macular Degeneration
- Interventions
- 4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea, sham injection
- Drug
- Lead sponsor
- Lpath, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 44
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
- Conditions
- Hearing Loss, Adult-Onset, Hearing Loss, Age-Related
- Interventions
- Patient Navigation Program for Hearing Health Care
- Behavioral
- Lead sponsor
- Matthew Bush, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 9
- States / cities
- Campbellsville, Kentucky • Campton, Kentucky • Elkton, Kentucky + 4 more
- Conditions
- Sarcopenia, Gait Disorders in Old Age, Muscle Weakness
- Interventions
- BIO101, Placebo
- Drug
- Lead sponsor
- Biophytis
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 19
- States / cities
- Banning, California • Garden Grove, California • San Diego, California + 15 more
- Conditions
- Macular Degeneration
- Interventions
- ranibizumab, verteporfin
- Drug
- Lead sponsor
- Texas Retina Associates
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 3
- States / cities
- Santa Barbara, California • Ann Arbor, Michigan • Arlington, Texas
- Conditions
- Memory Impairment
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 45 Years to 70 Years
- Enrollment
- 139 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Wet Macular Degeneration, Wet Age-related Macular Degeneration
- Interventions
- Ziv-Aflibercept 25 MG/ML [Zaltrap], Ranibizumab
- Drug
- Lead sponsor
- Kapil Kapoor
- Other
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Virginia Beach, Virginia
- Conditions
- Diabetic Macular Edema
- Interventions
- LKA651, Lucentis
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • Rancho Cordova, California • Miami, Florida + 4 more
- Conditions
- Age-Related Macular Degeneration, Alzheiner's Disease, AMD
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 45 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 557 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 65
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more